Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yu Fu
- Phone Number: 13671185050
- Email: lilac_fu@126.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking University Third Hospital
-
Contact:
- Yu Fu
- Phone Number: 13671185050
- Email: lilac_fu@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Meet the diagnostic criteria for migraine in the International Classification of Headache (ICHD-3);
- Confirmation of patent foramen ovale through transthoracic echocardiography(TTE) or transesophageal echocardiography(TEE)/right heart contrast echocardiography
- Agree to participate in the study and sign the informed consent form.
Exclusion Criteria:
- Can not sign the informed consent form or cooperate with follow-up.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Conservative group
Don't use antiplatelet drugs or undergo patent foramen ovale closure.
|
Receive no antipaletet drug treatment and surgery
|
|
Antiplatelet group
The application of antiplatelet drug.
|
Use of antipaletet drugs.
|
|
PFO group
Receive a patent foramen ovale closure surgery.
|
Receive the surgery of Patent Foramen Ovale
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The changes of migraine attacks
Time Frame: 3 months, 6 months, 1 year, 2 years and 3 years
|
Migraine attacks are an important indicator of improvement in symptoms.
The comparison measures included headache frequency, duration, pain degree, VAS scores, HIT-6 scores, HAMA, HAMD, and PSQI.
|
3 months, 6 months, 1 year, 2 years and 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Cardiovascular Diseases
- Heart Diseases
- Headache Disorders, Primary
- Headache Disorders
- Congenital Abnormalities
- Cardiovascular Abnormalities
- Heart Defects, Congenital
- Heart Septal Defects, Atrial
- Heart Septal Defects
- Migraine Disorders
- Foramen Ovale, Patent
Other Study ID Numbers
Other Study ID Numbers
- M2024296
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.